Metabolic Risks Remain Largely Unmonitored In Medicaid Patients Taking Antipsychotics

Metabolic Risks Remain Largely Unmonitored In Medicaid Patients Taking Antipsychotics

Posted on 17. Jan, 2010 by in Discoveries and Innovations

Despite government warnings and professional recommendations about diabetes risks associated with second-generation antipsychotic drugs, fewer than one-third of Medicaid patients who are treated with these medications undergo tests of blood glucose or lipid levels, according to a report in the January issue of Archives of General Psychiatry, one of the JAMA/Archives journals.

In 2003, the Food and Drug Administration (FDA) began requiring a warning on labels of second-generation antipsychotics that glucose levels should be monitored in patients with diabetes, at risk for the disease or with symptoms of high blood glucose.

Elaine H. Morrato, Dr.P.H., M.P.H., of the University of Colorado Denver, and colleagues studied laboratory  claims data from the Medicaid population of three states (California, Missouri and Oregon) between 2002 and 2005. Metabolic testing (testing of blood glucose and lipid levels) rates were compared between a group of 109,451 patients receiving second-generation antipsychotics and a control group of 203,527 who began taking albuterol (an asthma drug) but not an antipsychotic. Rates were also compared before and after the FDA warning.

Initial testing rates for patients treated with second-generation antipsychotics were low—27 percent underwent glucose testing and 10 percent underwent lipid testing. The FDA warning was not associated with any increase in glucose testing and only a marginal increase in lipid testing rates (1.7 percent). “Testing rates and trends in second-generation antipsychotic–treated patients were not different from background rates observed in the albuterol control group,” the authors write.

New prescriptions of olanzapine, which carries a higher metabolic risk, declined during the warning period. Prescriptions of the lower-risk drug aripiprazole increased, but this may also be attributable to the elimination of prior authorization for the drug in California during the same timeframe.

 Article is available here: http://www.redorbit.com/news/health/1804364/metabolic_risks_remain_largely_unmonitored_in_medicaid_patients_taking_antipsychotics/index.html?source=r_health

Leave a Reply

You must be logged in to post a comment.